In this study we show that SV.IL-12 combined with an agonistic OX40 antibody can eliminate ovarian cancer in a mouse model and further prevent tumors in mice rechallenged with tumor cells after approximately 5 months. Here, TNFRSF4 is linked to ovarian carcinoma.